Follow the signal through a synapse #
Neurons receive information, integrate it, and communicate with other cells. In a common synaptic sequence, an electrical signal reaches an axon terminal, calcium-dependent processes promote release from vesicles, and a transmitter acts on receptors. The signal is limited by diffusion, uptake, enzymatic breakdown, and feedback. This sequence supplies several possible drug targets; there is no single universal 'brain chemical' target shared by all psychiatric medicines.
Ionotropic receptors are linked to ion channels and can change electrical activity rapidly. Metabotropic receptors signal through intracellular pathways, including G proteins and second messengers. Intracellular responses can influence protein function, gene expression, and plasticity. An immediate change at a molecular target and a later change in mood or behavior occur at different levels of explanation; the first does not guarantee the second.
Major transmitter systems #
| System | Broad relevance | Illustrative drug connection |
|---|---|---|
| Dopamine | Movement, salience, reward, motivation, and other circuit functions | D2 antagonism or partial agonism; DAT inhibition. |
| Serotonin | Mood, anxiety-related processing, sleep, appetite, and other functions | SERT inhibition and receptor-specific actions. |
| Norepinephrine | Arousal, attention, autonomic responses | NET inhibition and adrenergic receptor actions. |
| GABA | Major inhibitory signaling | GABA-A positive allosteric modulation. |
| Glutamate | Major excitatory signaling and plasticity | Selected receptor and channel-related mechanisms. |
| Acetylcholine | Cognition and autonomic functions | Cholinesterase inhibition or muscarinic actions. |
| Histamine and orexin | Wakefulness and arousal networks | H1 antagonism and orexin-receptor antagonism. |
Calling dopamine the 'pleasure chemical' or serotonin the 'happiness chemical' hides important distinctions. The same transmitter acts in different pathways with different receptor subtypes. A proposed mechanism for a disorder is also not equivalent to an established abnormality in every person with that diagnosis.
Affinity, efficacy, and receptor actions #
Affinity describes how readily a substance binds to a target under specified conditions. Efficacy describes the response it produces after binding. A full agonist produces a maximal response within the experimental system; a partial agonist produces less maximal activation. An antagonist blocks agonist effects without the same activating action. An inverse agonist reduces constitutive activity where that property exists. These terms describe target behavior, not how 'strong' the whole medicine is clinically.
A partial agonist can have different net effects depending on endogenous transmitter activity and the system examined. An allosteric modulator acts at a different site from the primary transmitter-binding site and changes the response to that transmitter. Benzodiazepine-related GABA-A modulation illustrates why enhancing the effect of a transmitter differs from directly replacing it. Receptor occupancy, clinical efficacy, and adverse effects are related but not interchangeable measurements.
Transporters, enzymes, and channels #
Reuptake transporters return transmitters to cells. Blocking SERT, NET, or DAT alters transmitter availability rather than directly stimulating every receptor for that transmitter. Enzyme inhibition can reduce transmitter breakdown, as with monoamine oxidase or acetylcholinesterase. Voltage-sensitive channels and ligand-gated channels regulate signaling in different ways. Medicines can also influence intracellular signaling without one definitive receptor explanation, as illustrated by lithium.
Class labels often summarize only part of a medicine's pharmacology. Drugs grouped as antidepressants, antipsychotics, anticonvulsants, or mood stabilizers may have different approved uses, effects, and risks. An anticonvulsant mechanism does not establish efficacy in bipolar disorder, and an antipsychotic label does not imply identical metabolic or movement effects across the class.
How the body changes exposure #
| Process | Meaning | Clinical implication |
|---|---|---|
| Absorption | Entry into systemic circulation | Route, food, release formulation, and bioavailability can matter. |
| Distribution | Movement into tissues and binding | Plasma concentration does not always equal concentration at the target. |
| Metabolism | Chemical transformation | Active metabolites and enzyme interactions can extend or change effects. |
| Excretion | Removal from the body | Renal function and other physiological changes can alter exposure. |
Half-life describes a concentration's decline under the relevant conditions. Repeated exposure can accumulate toward a steady state; active metabolites or nonlinear kinetics complicate simple predictions. An immediate-release tablet and an extended-release tablet may contain the same ingredient but differ in concentration over time. A printed strength states product content, not the daily regimen or interchangeable administration instructions.
Pharmacokinetic and pharmacodynamic interactions #
A pharmacokinetic interaction changes exposure: an enzyme inhibitor may reduce clearance, while an inducer may increase it. Starting or stopping either can matter. The result depends on the specific pathway, medicine, metabolite, and therapeutic margin. A pharmacodynamic interaction changes combined effects without necessarily changing concentrations: sedatives may add impairment, serotonergic medicines may add serotonin-related risk, and several medicines can contribute to hypotension.
Consider medical illness, tobacco smoke, over-the-counter treatments, and supplements as part of the interaction history. Lithium illustrates renal handling interactions; clozapine illustrates exposure changes around smoking and infection; lamotrigine illustrates glucuronidation-related interactions; fluoxetine illustrates persistence after the last dose. The category 'psychiatric medicines' is too narrow for a complete reconciliation.
Use monitoring to answer a clinical question #
- Define the target symptoms and functioning before judging benefit.
- Document baseline findings that could later be mistaken for adverse effects.
- Identify clinically relevant physical vulnerabilities and concurrent medicines.
- Select observations or investigations that address a real risk of the actual product.
- Record timing, adherence, interruptions, and exposure changes when interpreting a result.
- Distinguish partial benefit, adverse effects, and uncertainty rather than reducing them to a single response label.
Therapeutic drug monitoring is particularly useful for selected medicines and questions, such as altered clearance, adherence, or toxicity. A concentration does not by itself establish safety, efficacy, or the cause of a new symptom. Pregnancy, childhood, older age, hepatic or renal impairment, and formulation differences can require distinct interpretation. Educational mechanisms support clinical reasoning; they do not generate a diagnosis, medicine change, or declaration of safety.